miR-135a Contributes to Paclitaxel Resistance in Tumor Cells Both in Vitro and in Vivo

Oncogene - United Kingdom
doi 10.1038/onc.2011.148
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeted Delivery of Paclitaxel to Tumor Cells: Synthesis and in Vitro Evaluation

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2010English

Downregulation of miR‑200c‑3p Contributes to the Resistance of Breast Cancer Cells to Paclitaxel by Targeting SOX2

Oncology Reports
MedicineCancer ResearchOncology
2018English

MiR-1204 Sensitizes Nasopharyngeal Carcinoma Cells to Paclitaxel Bothin Vitroandin Vivo

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2015English

MLN8054, an Inhibitor of Aurora a Kinase, Induces Senescence in Human Tumor Cells Both in Vitro and in Vivo

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2010English

Resistance of Human Tumor Cells in Vitro to Oxidative Cytolysis.

Journal of Clinical Investigation
Medicine
1985English

Cell Division Cycle 6 Promotes Mitotic Slippage and Contributes to Drug Resistance in Paclitaxel-Treated Cancer Cells

PLoS ONE
Multidisciplinary
2016English

The Alkylphospholipid, Perifosine, Radiosensitizes Prostate Cancer Cells Both in Vitro and in Vivo

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2011English

The Hedgehog Inhibitor GANT61 Sensitizes Prostate Cancer Cells to Ionizing Radiation Both in Vitro and in Vivo

Oncotarget
Oncology
2016English

Dysregulation of miR-106a and miR-591 Confers Paclitaxel Resistance to Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy